Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights

New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value propositionUpsized $20 million financing led by U.S. institutional investors is expected to fund key value inflection points through planned commercial launch of next-generation Novasight Hybrid™ System in H1 2026U.S. FDA 510(k) submission remains on track for calendar Q3 2025 TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) ...